GI
Giant Industries, Inc.
Set alert
8.00 0.00 0.00%
7.95 Day range 8.00
3.64 52-week range 9.47
- Open
- 8.00
- Prev close
- 8.00
- Mkt cap
- 0
- Vol
- 14.18K
- Avg vol
- 128.52K
- EPS
- -3.59
- P/E
- -2.23
More statistics
- Low
- 7.95
- High
- 8.00
- Earnings
- Nov 24, 2016
Next earnings
Nov 24, 2016
Expected Nov 24, 2016. Consensus EPS estimate -0.52.
Financials — quick view
GI Revenue — quarterly 19.15M
GI Net income — quarterly -17.36M
GI EPS — quarterly -0.69
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 24, 2016 | Sep 1, 2016 | -0.52 | — | — | — |
| Aug 3, 2016 | Jun 1, 2016 | -0.52 | — | — | — |
| May 4, 2016 | Mar 1, 2016 | -0.54 | — | — | — |
| Mar 3, 2016 | Dec 1, 2015 | -0.60 | — | — | — |
| Nov 5, 2015 | Sep 1, 2015 | -0.54 | — | — | — |
| Aug 6, 2015 | Jun 1, 2015 | -0.90 | — | — | — |
News
- Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
- Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patien
- Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
- Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
- Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
- Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
- Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
- FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
- Alight Adds Cylinder and Leap to Partner Network
Your note
Sign in to keep a note on GI — it syncs with the Stock Master app.